¹⁸F-C2Am: a targeted imaging agent for detecting tumor cell death in vivo using positron emission tomography.

ABSTRACT:

Introduction

Trialing novel cancer therapies in the clinic would benefit from imaging agents that can detect early evidence of treatment response. The timing, extent and distribution of cell death in tumors following treatment can give an indication of outcome. We describe here an ¹⁸F-labeled derivative of a phosphatidylserine-binding protein, the C2A domain of Synaptotagmin-I (C2Am), for imaging tumor cell death in vivo using PET.

Methods

A one-pot, two-step automated synthesis of N-(5-[¹⁸F]fluoropentyl)maleimide (60 min synthesis time, > 98% radiochemical purity) has been developed, which was used to label the single cysteine residue in C2Am within 30 min at room temperature. Binding of ¹⁸F-C2Am to apoptotic and necrotic tumor cells was ass

SUBMITTER: Bulat F 

PROVIDER: S-EPMC7726082 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature